2021
DOI: 10.1177/1971400921990766
|View full text |Cite
|
Sign up to set email alerts
|

Survival prediction in glioblastoma on post-contrast magnetic resonance imaging using filtration based first-order texture analysis: Comparison of multiple machine learning models

Abstract: Objective Magnetic resonance texture analysis (MRTA) is a relatively new technique that can be a valuable addition to clinical and imaging parameters in predicting prognosis. In the present study, we investigated the efficacy of MRTA for glioblastoma survival using T1 contrast-enhanced (CE) images for texture analysis. Methods We evaluated the diagnostic performance of multiple machine learning models based on first-order histogram statistical parameters derived from T1-weighted CE images in the survival strat… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
12
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
10

Relationship

4
6

Authors

Journals

citations
Cited by 14 publications
(12 citation statements)
references
References 42 publications
0
12
0
Order By: Relevance
“…However, the development of a precise model for predicting the initial response to TACE therapy is desired, and radiomics is a promising method that involves the extraction of several quantitative features from radiology images, which could be feasibly used (12,13). Previous studies have shown that conventional machine learning (cML) based on radiomics could be used to significantly predict clinical outcomes in cancers (14)(15)(16)(17)(18). In our previous studies, radiomics models could effectively predict microvascular invasion and progression-free survival before hepatectomy (19).…”
Section: Introductionmentioning
confidence: 99%
“…However, the development of a precise model for predicting the initial response to TACE therapy is desired, and radiomics is a promising method that involves the extraction of several quantitative features from radiology images, which could be feasibly used (12,13). Previous studies have shown that conventional machine learning (cML) based on radiomics could be used to significantly predict clinical outcomes in cancers (14)(15)(16)(17)(18). In our previous studies, radiomics models could effectively predict microvascular invasion and progression-free survival before hepatectomy (19).…”
Section: Introductionmentioning
confidence: 99%
“…Amongst the most studied pathologies depicted through MRI protocols are the central nervous system tumors, neuroradiology comprising 19.71% of the international literature tackling radiomics-based tools, being the fastest developing research domain, with an annual growth rate of published papers of 316.02%, between 2013–2018 [ 51 ]. The greatest advantage that texture analysis brings in this context is the preoperative aggressiveness assessment of gliomas, differentiating low-grade gliomas from glioblastoma multiforme with an accuracy of 89% [ 52 ], having the potential of predicting the short (<12 months) or long-term survival rate (>24 months), based on the identified heterogeneity degree [ 53 ]. Finally, this emerging research area finds applicability in benign pathologies as well, being used for instance in differentiating endometriomas from hemorrhagic ovarian cysts, outperforming the classical pathognomonic “T2 dark spots” sign in terms of sensitivity (55.17%, versus 75%) and both “T2 shading” and “T2 dark spots” signs when it comes to specificity (35.71% and 64.29% versus 100%) [ 54 ].…”
Section: Discussionmentioning
confidence: 99%
“…The radiomics algorithm offers an unprecedented opportunity to improve cancer decision-making in a low-cost and non-invasive manner. Previous studies have shown that radiomics models of radiology images are significantly associated with clinical outcomes in cancer patients (17)(18)(19)(20)(21). We previously found that a radiomics model based on CT images could precisely predict microvascular invasion in HCC patients and the machine learning algorithm could be used to predict clinic outcome in cancer (22,23).…”
Section: Introductionmentioning
confidence: 98%